Dr. Mark Vander Lugt, MD
Claim this profileUniversity of Michigan Hospitals - Michigan Medicine
Studies Krabbe Disease
Studies Severe Combined Immunodeficiency
6 reported clinical trials
12 drugs studied
Area of expertise
1Krabbe Disease
GALC positive
psychosine positive
2Severe Combined Immunodeficiency
HLA positive
CD62L negative
CD45RO positive
Affiliated Hospitals
Clinical Trials Mark Vander Lugt, MD is currently running
Stem Cell Transplantation
for Leukemia
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well this treatment works in patients with hematologic malignancies.
Recruiting1 award Phase 2
Stem Cell Transplant Conditioning
for SCID
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related donor transplants. The study will test if patients receiving transplant using either a low dose busulfan or a medium dose busulfan will have immune recovery of both T and B cells, measured by the ability to respond to immunizations after transplant. The exact regimen depends on the subtype of SCID the patient has. Donors used for transplant must be unrelated or half-matched related (haploidentical) donors, and peripheral blood stem cells must be used. To minimize the chance of graft-versus-host disease (GVHD), the stem cells will have most, but not all, of the T cells removed, using a newer, experimental approach of a well-established technology. Once the stem cell transplant is completed, patients will be followed for 3 years. Approximately 9-18 months after the transplant, vaccinations will be administered, and a blood test measuring whether your child's body has responded to the vaccine will be collected.
Recruiting1 award Phase 244 criteria
More about Mark Vander Lugt, MD
Clinical Trial Related3 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Mark Vander Lugt, MD has experience with
- FBX-101
- Fludarabine
- Busulfan
- Cell Processing For TCRαβ+/CD19+ Depletion
- Bone Marrow Hematopoietic Stem Cell Transplantation
- Cyclophosphamide
Breakdown of trials Mark Vander Lugt, MD has run
Krabbe Disease
Severe Combined Immunodeficiency
Myelodysplastic syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mark Vander Lugt, MD specialize in?
Mark Vander Lugt, MD focuses on Krabbe Disease and Severe Combined Immunodeficiency. In particular, much of their work with Krabbe Disease has involved GALC positive patients, or patients who are psychosine positive.
Is Mark Vander Lugt, MD currently recruiting for clinical trials?
Yes, Mark Vander Lugt, MD is currently recruiting for 2 clinical trials in Ann Arbor Michigan. If you're interested in participating, you should apply.
Are there any treatments that Mark Vander Lugt, MD has studied deeply?
Yes, Mark Vander Lugt, MD has studied treatments such as FBX-101, Fludarabine, Busulfan.
What is the best way to schedule an appointment with Mark Vander Lugt, MD?
Apply for one of the trials that Mark Vander Lugt, MD is conducting.
What is the office address of Mark Vander Lugt, MD?
The office of Mark Vander Lugt, MD is located at: University of Michigan Hospitals - Michigan Medicine, Ann Arbor, Michigan 48109 United States. This is the address for their practice at the University of Michigan Hospitals - Michigan Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.